Antineoplastic drugs and drug-induced liver damage with cholestasis
https://doi.org/10.33667/2078-5631-2020-19-47-54
Abstract
The number of cases of drug-induced liver injury (DILI) has been increasing since the 1990s. DILIs cause up to 40,000 deaths each year. One of the leaders in the number of DILIs are antineoplastic drugs ms, such as alkylating agents, antimetabolites, targeted drugs, monoclonal antibodies, etc. One of the most effective and safe strategies for the treatment and prevention of DILI is to use hepatoprotective drugs. Currently, on the market of the Russian Federation, is available novel drug Heptrong® (does not have an International Non-proprietary Name), which has anti-inflammatory, antioxidant activity and the ability to stabilize and reduce the permeability of hepatocyte membranes, suppress the activity 5-lipoxygenase, a decrease in the synthesis of leukotriene B4, interleukin-1, interleukin-6, which are pro-inflammatory cytokines. The drug activates the antitoxic function of the liver, improves its protein- and lipid-synthesizing functions. Heptrong® neutralizes the processes of inflammation in the liver, thereby reducing the severity of the clinical manifestations of drug-induced lesions.
About the Authors
A. P. Pereverzev
Russian Medical Academy for Continuing Professional Education
Russian Federation
Moscow
Russian Federation
Moscow
O. D. Ostroumova
Russian Medical Academy for Continuing Professional Education; First Moscow State Medical University n.a. I.M. Sechenov
Russian Federation
Moscow
Russian Federation
Moscow
References
1. Yu YC, Mao YM, Chen CW, et al. CSH guidelines for the diagnosis and treatment of drug-induced liver injury. Hepatol Int. 2017; 11 (3): 221–241. DOI: 10.1007/s12072–017–9793–2.
2. Hillman L, Gottfried M, Whitsett M, et al. Clinical Features and Outcomes of Complementary and Alternative Medicine Induced Acute Liver Failure and Injury [published correction appears in Am J Gastroenterol. 2016 Oct; 111 (10): 1504]. Am J Gastroenterol. 2016; 111 (7): 958–965. DOI: 10.1038/ajg.2016.114.
3. Галимова С. Ф. Лекарственные поражения печени (часть 1). Трансплантология. 2011. № 1. С. 13–22.
4. Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2014; 109 (7): 950–967. DOI: 10.1038/ajg.2014.131.
5. Leone A, Nie A, Brandon Parker J, et al. Oxidative stress/reactive metabolite gene expression signature in rat liver detects idiosyncratic hepatotoxicants. Toxicol Appl Pharmacol. 2014; 275 (3): 189–197. DOI: 10.1016/j.taap.2014.01.017.
6. Lo Re V 3rd, Haynes K, Forde KA, et al. Risk of Acute Liver Failure in Patients With Drug-Induced Liver Injury: Evaluation of Hy’s Law and a New Prognostic Model. Clin Gastroenterol Hepatol. 2015; 13 (13): 2360–2368. DOI: 10.1016/j.cgh.2015.06.020.
7. Bunchorntavakul C, Reddy KR. Review article: herbal and dietary supplement hepatotoxicity. Aliment Pharmacol Ther. 2013; 37 (1): 3–17. DOI: 10.1111/apt.12109.
8. Ostapowicz G, Fontana RJ, Schiødt FV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med. 2002; 137 (12): 947–954. DOI: 10.7326/0003–4819–137–12–200212170–00007.
9. Björnsson ES. Epidemiology and risk factors for idiosyncratic drug-induced liver injury. Semin Liver Dis. 2014; 34 (2): 115–122. DOI: 10.1055/s-0034–1375953.
10. Лазебник Л. Б., Голованова Е. В., Хлынова О. В., Алексеенко С.А., Арямкина О.Л., Бакулин И.Г., Бакулина Н. В., Барановский А.Ю., Бондаренко О. А., Варганова А. Н., Волкова Т. В., Вологжанина Л.Г., Волчегорский И.А., Демичева Т.П., Долгушина А. И., Маев И. В., Минушкин О. Н., Райхельсон К.Л., Смирнова Е. Н., Тарасова Л. В., Цыганова Ю. В. Лекарственные поражения печени (ЛПП) у взрослых. Экспериментальная и клиническая гастроэнтерология. 2020; 174 (2): 29–54. DOI: 10.31146/1682–8658-ecg-174–2–29–54.
11. Laura Morales M., Natalia Vélez L., Octavio Germán Muñoz M. Hepatotoxicity: A Drug-Induced Cholestatic Pattern. Rev Col Gastroenterol. 2016; 31 (1): 34–45.
12. Bhamidimarri KR, Schiff E. Drug-induced cholestasis. Clin Liver Dis. 2013; 17 (4): 519–vii. DOI: 10.1016/j.cld.2013.07.015.
13. Tajiri K, Shimizu Y. Practical guidelines for diagnosis and early management of drug-induced liver injury. World J Gastroenterol. 2008; 14 (44): 6774–6785. DOI: 10.3748/wjg.14.6774.
14. Райхельсон К.Л., Пальгова Л. К., Кондрашина Э.А., Марченко Н.В., Барановский А.Ю. Лекарственные поражения печени. Клинические рекомендации для врачей. СПб. 2017.116 с.
15. LiverTox® – ресурс для специалистов практического здравоохранения по вопросам лекарственнного поражения печени. Available at: https://livertox.nih.gov/Phenotypes_lact.html (дата обращения: 10.09.2020).
16. James E. Tisdale, Douglas A. Miller. Drug-Induced Diseases: Prevention, Detection, and Management. Am J Pharm Educ. 2018. 3rd edition. ISBN: 978–1–58528–530–3.
17. Журнал «Новости GMP». Available at: https://gmpnews.ru/2019/09/dsm-grouppredstavlyaet-obzor-gospitalnyx-zakupok-zai-polugodie-2019-goda/ (дата обращения: 10.09.2020).
18. Д. Б. Корман. Противоопухолевые препараты, применяемые для лечения злокачественных опухолей органов пищеварения: механизмы действия и фармакокинетика. Available at: http://www.oncology.ru/cathedra/lecture/lec/08.pdf (дата обращения: 10.09.2020).
19. Государственный реестр лекарственных средств. Available at: https://grls.rosminzdrav.ru (дата обращения: 10.09.2020).
20. Grigorian A, O’Brien CB. Hepatotoxicity Secondary to Chemotherapy. J Clin Transl Hepatol. 2014; 2 (2): 95–102. DOI: 10.14218/JCTH.2014.00011.
21. Информационный ресурс для специалистов практического здравоохранения Drugbank. Available at: https://www.drugbank.ca (дата обращения: 10.09.2020).
22. Информационный ресурс VigiaccessTM по вопросам нежелательных реакций, собранным в международной базе данных нежелательных реакций VigiBase®. Available at: http://www.vigiaccess.org (дата обращения: 10.09.2020).
23. Dixit S, Hingorani M, Afzal P, Campbell AP. Temozolomide induced liver injury. Acta Neurol Belg. 2011; 111 (3): 249–251.
24. Björnsson ES, Gu J, Kleiner DE, et al. Azathioprine and 6-Mercaptopurine-induced Liver Injury: Clinical Features and Outcomes. J Clin Gastroenterol. 2017; 51 (1): 63–69. DOI: 10.1097/MCG.0000000000000568.
25. Robinson K, Lambiase L, Li J, Monteiro C, Schiff M. Fatal cholestatic liver failure associated with gemcitabine therapy. Dig Dis Sci. 2003; 48 (9): 1804–1808. DOI: 10.1023/a:1025415616592.
26. Kannaiyan R, Mahadevan D. A comprehensive review of protein kinase inhibitors for cancer therapy. Expert Rev Anticancer Ther. 2018; 18 (12): 1249–1270. DOI: 10.1080/14737140.2018.1527688.
27. Peddi PF. Hormone receptor positive breast cancer: state of the art. Curr Opin Obstet Gynecol. 2018; 30 (1): 51–54. DOI: 10.1097/GCO.0000000000000424.
28. Bessone F, Lucena MI, Roma MG, et al. Cyproterone acetate induces a wide spectrum of acute liver damage including corticosteroid-responsive hepatitis: report of 22 cases. Liver Int. 2016; 36 (2): 302–310. DOI: 10.1111/liv.12899.
29. Ивашкин В.Т., Барановский А.Ю., Райхельсон К.Л., Пальгова Л.К., Маевская МВ, Кондрашина ЭА и др. Лекарственные поражения печени (клинические рекомендации для врачей). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2019; 29 (1): 101–31 https://doi.org/10.22416/1382-4376-2019-29-1-101-131.
30. Сычев Д. А., Остроумова О. Д., Переверзев А.П., Кочетков А.И., Остроумова Т.М., Клепикова М. В., Аляутдинова И. А., Голобородова И. В. Лекарственно-индуцированные заболевания: подходы к диагностике, коррекции и профилактике. Фармаконадзор. Фарматека. 2020; 27 (6): 113–126. https://dx.doi.org/10.18565/pharmateca.2020.6.113-126
31. Информационный ресурс для специалистов здравоохранения «Vidal». Available at: https://www.vidal.ru/drugs/geptrong_24139 (дата обращения: 10.09.2020).
32. Официтальный сайт препарата Гептронг. Available at: https://www.geptrong.com/geptrong/ (дата обращения: 10.09.2020).
33. European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; Clinical Practice Guideline Panel: Chair:; Panel members; EASL Governing Board representative: EASL Clinical Practice Guidelines: Drug-induced liver injury. J Hepatol. 2019; 70 (6): 1222–1261. DOI: 10.1016/j.jhep.2019.02.014.
Review
For citations:
Pereverzev A.P., Ostroumova O.D. Antineoplastic drugs and drug-induced liver damage with cholestasis. Medical alphabet. 2020;1(19):47-54. (In Russ.) https://doi.org/10.33667/2078-5631-2020-19-47-54
Views:
616
Email this article 